It is hoped the move will ensure Teva secures the top position in the Eurpean generics market. – notably Germany, Spain, Italy and France.
In addition to this, the acquisition of Ratiopharm – who have strong know-how in biocimilars, should thus strengthen Teva’s portfolio of biopharmaceutical and biogeneric products.
Over the years, Teva has been no stranger to acquisitions – it’s last major one being that of Barr Pharmaceutical s, a US-based multinational generic pharmaceutical company. This boosted Teva’s portfolio of generuc pharmaceutical products, as well as women’s health products.
Are you looking for a job in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs online now.